Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019"

By Brian Orelli, PhD - Jun 29, 2016 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA leaves the biotech hanging.

Image source: Getty Images.

What: Esperion Therapeutics ( ESPR 0.58% ) is down about 40% at 12:20 p.m. EDT after updating investors on the pathway to approval for its cholesterol-lowering drug bempedoic acid, which used to go by the moniker ETC-1002.

So what: The company has always planned on running two types of clinical trials: one to show that bempedoic acid lowers cholesterol, and a second longer study to show that lowering cholesterol results in fewer cardiovascular events -- heart attacks and strokes, for instance. The hope was that the cholesterol-lowering study would be enough for approval, and the cardiovascular outcomes study would simply be added to the label later.

And that's exactly what's happening in Europe. After talking with regulators there, Esperion Therapeutics plans to submit a marketing application showing that bempedoic acid can lower cholesterol by 2019, and then follow it up with an application by 2022 for lowering cardiovascular disease risk.

In the U.S. though, the pathway to approval has been a moving target.

In August 2015, after the end-of-phase 2 meeting with the FDA, management said lowering low density lipoprotein cholesterol (LDL-C) -- that's the bad kind -- would be good enough for approval:

The FDA confirmed that LDL-C remains an acceptable clinical surrogate endpoint for the approval of an LDL-C lowering therapy such as ETC-1002.

By the time the meeting notes arrived a month later, the tone had changed, and management hedged on the possibility that it might actually need an outcomes trial for approval:

FDA has encouraged the Company to initiate a cardiovascular outcomes trial promptly, which would be well under way at the time of the New Drug Application submission and review, since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval.

And then yesterday, Esperion Therapeutics' management threw up their hands and said the FDA has no idea whether cholesterol lowering will be enough when the company completes its trial in 2019:

The Agency indicated its position regarding an LDL-C lowering indication could be impacted by potential future changes in their view of LDL-C lowering as a surrogate endpoint or the possibility of a shift in the future standard-of-care for statin intolerant patients with elevated LDL-C levels.

Now what: The FDA's view on LDL-C lowering might change because Amgen's ( AMGN -2.26% ) Repatha and Praluent, sold by Sanofi ( SNY -1.33% ) and Regeneron Pharmaceuticals ( REGN -2.73% ), are scheduled to release cardiovascular outcome studies in the coming years. If the drugs, which lower cholesterol, don't show improved cardiovascular outcomes, Esperion will have a hard time arguing that bempedoic acid should be approved just because it can lower cholesterol.

Unfortunately, if Amgen, Sanofi, and Regeneron are able to show that their drugs improve cardiovascular outcomes, it could be a "shift in the future standard-of-care" that management cited as one of the FDA's reasons for changing its opinion on lowering cholesterol.

It seems, then, that Esperion and its investors should be hoping that Amgen, Sanofi, and Regeneron are able to show that the drugs lower cardiovascular events, but not by enough to make them so great that the FDA thinks it's risky to have bempedoic acid on the market with its unproven cardiovascular outcomes.

Or they can just wait until 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Esperion Therapeutics Stock Quote
Esperion Therapeutics
ESPR
$8.73 (0.58%) $0.05
Sanofi Stock Quote
Sanofi
SNY
$47.57 (-1.33%) $0.64
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$198.88 (-2.26%) $-4.59
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$636.53 (-2.73%) $-17.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.